With a long history in dermatology and rheumatology, TNF inhibitors can not only improve psoriasis and psoriatic arthritis, but they also may reduce comorbid cardiovascular risks and work better combined with methotrexate. Low doses of cyclosporine may be effective at treating the psoriasis reaction when topicals have proven ineffective. Aggressively managing TNF-induced reactions can help patients stay on drugs that are working for other challenging diseases.
A new drug to treat moderate-to-severe plaque psoriasis carries a black box warning that suicidal ideas and behavior, including completed suicides, have occurred in patients during the drug’s clinical trials.
A pioneering summit between healthcare payers and groups pursuing standardized outcome measures in dermatology has revealed that payers want outcome measures that are published, universally accepted and practical both for clinicians and payers.
The FDA is evaluating biosimilar medications for use in the United States. The approval of these medications in the next few years could mean big changes for dermatologists and their psoriasis patients
As research advances understanding of psoriasis, drug development evolves to address various pathways to disease. A number of possibilities, now in clinical trials, appear safe, effective and promising with improved long-term clearance rates.